While we are advancing the development of our later-stage product candidates in multiple ongoing clinical programs, we are seeking strategic alliances to broaden the geographic reach of our development programs or to advance our earlier-stage technologies and product candidates.

Our innovative platform technologies are driving the development of a portfolio of first-in-class, patented monoclonal antibody-based product candidates, and there are numerous opportunities for strategic alliances.

For further information, please contact our Business Development department at: This e-mail address is being protected from spambots. You need JavaScript enabled to view it